Key Points
- CFO Brett Hale sold 24,188 shares on March 23 at an average price of $1.21 for $29,267.48, cutting his ownership by 8.06% to 275,812 shares valued at $333,732.52.
- Hyperfine beat EPS estimates for the quarter (reported a loss of $(0.06) vs. consensus $(0.08)) with $5.29M in revenue, but remains unprofitable with a negative net margin (−262.29%) and negative return on equity.
- The stock trades around $1.17 (52‑week range $0.53–$2.22) with a $113.7M market cap; analysts are mixed (average rating "Hold" and target $1.45) and institutional ownership is about 15%.
Hyperfine, Inc. (NASDAQ:HYPR - Get Free Report) CFO Brett Hale sold 24,188 shares of the company's stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $1.21, for a total value of $29,267.48. Following the completion of the transaction, the chief financial officer directly owned 275,812 shares of the company's stock, valued at $333,732.52. This trade represents a 8.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Hyperfine Stock Up 1.7%
Shares of Hyperfine stock opened at $1.17 on Thursday. Hyperfine, Inc. has a 52 week low of $0.53 and a 52 week high of $2.22. The firm's 50 day moving average is $1.16 and its two-hundred day moving average is $1.20. The firm has a market capitalization of $113.69 million, a P/E ratio of -2.66 and a beta of 1.09.
Hyperfine (NASDAQ:HYPR - Get Free Report) last issued its earnings results on Wednesday, March 18th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $5.29 million during the quarter, compared to analysts' expectations of $5.30 million. Hyperfine had a negative net margin of 262.29% and a negative return on equity of 95.09%. As a group, research analysts expect that Hyperfine, Inc. will post -0.57 earnings per share for the current fiscal year.
Institutional Trading of Hyperfine
Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Hyperfine by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company's stock valued at $5,092,000 after purchasing an additional 190,136 shares during the last quarter. Tortoise Investment Management LLC acquired a new position in shares of Hyperfine in the third quarter valued at approximately $65,000. Kathmere Capital Management LLC purchased a new stake in shares of Hyperfine during the fourth quarter worth approximately $51,000. Sanctuary Advisors LLC lifted its holdings in shares of Hyperfine by 130.9% during the fourth quarter. Sanctuary Advisors LLC now owns 39,938 shares of the company's stock worth $39,000 after purchasing an additional 22,638 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Hyperfine by 21.4% during the fourth quarter. Geode Capital Management LLC now owns 815,986 shares of the company's stock worth $799,000 after purchasing an additional 143,975 shares during the period. 15.03% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have issued reports on HYPR. Zacks Research raised Hyperfine to a "hold" rating in a report on Thursday, March 19th. Lake Street Capital boosted their target price on Hyperfine from $2.00 to $2.50 and gave the company a "buy" rating in a report on Thursday, March 19th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Hyperfine in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $1.45.
Read Our Latest Report on Hyperfine
About Hyperfine
(
Get Free Report)
Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company's flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.
The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient's bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
